- Research works
- 99 ▲ 32% vs 2013–17
- Citations
- 1.3k 12.8 per fractional work
- Top-10% rate
- 10.0% record average 16.5%
- Open access
- 40% world 28%
Not ranked overall: Cell Biologics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
What does Cell Biologics (United States) specialise in?
Where its research is concentrated relative to its size: Medicine takes 3.1× the share of its output that it takes of world research.
- MedicineField · 22.3 works3.1×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 9.4×. Every wedge is a field page.
- Immunology and Microbiology 9.4×
- Pharmacology, Toxicology and Pharmaceutics 5.6×
- Medicine 3.1×
- Biochemistry, Genetics and Molecular Biology 3.1×
- Chemistry 1.4×
- Veterinary 1.3×
- Chemical Engineering 1.3×
- Neuroscience 0.8×
- Agricultural and Biological Sciences 0.3×
- Engineering 0.3×
- Materials Science 0.3×
- Energy 0.2×
- Health Professions 0.1×
- Computer Science 0.0×
- Environmental Science 0.0×
Which keywords describe research at Cell Biologics (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer Immunotherapy, Monoclonal Antibodies, Glycosylation, Therapeutic Antibodies, Immunotherapy, Monoclonal Antibody, Antibody Engineering and Fc Receptors.
- Public Health
- Cell Culture
- Immunogenicity
- Biopharmaceuticals
- Angiogenesis
- Tumor Antigen
- Dendritic Cells
- Radioimmunotherapy
- Cancer Treatment
- Immunity
- PET Imaging
- Antigen Presentation
- Inflammation
- CAR T Cells
- Fc Receptors
- Monoclonal Antibody
- Therapeutic Antibodies
- Monoclonal Antibodies
- Cancer Immunotherapy
- Glycosylation
- Immunotherapy
- Antibody Engineering
- Tumor Regression
- Chimeric Antigen Receptor
- Innate Immunity
- Breast Cancer
- HER2
- Trastuzumab
- Targeted Therapy
- Radiopharmaceuticals
- Epidemiology
- Tumor Microenvironment
- Oxidative Stress
- Immune Checkpoint Blockade
- PD-1 and PD-L1
- Prevention
- Nanoparticles
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 37 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 37 words, with their numbers
- Cancer Immunotherapy4▲ 78×2 topics
- Monoclonal Antibodies4▲ 127×3 topics
- Glycosylation4▲ 100×3 topics
- Therapeutic Antibodies4▲ 146×2 topics
- Immunotherapy3▲ 12×4 topics
- Monoclonal Antibody3▲ 157×2 topics
- Antibody Engineering3▲ 148×1 topic
- Fc Receptors3▲ 148×1 topic
- Tumor Regression3▲ 71×2 topics
- CAR T Cells3▲ 96×1 topic
- Chimeric Antigen Receptor3▲ 96×1 topic
- Inflammation2▲ 3.1×15 topics
- Innate Immunity2▲ 19×5 topics
- Antigen Presentation2▲ 69×2 topics
- Breast Cancer2▲ 25×2 topics
- PET Imaging2▲ 35×2 topics
- HER22▲ 200×1 topic
- Immunity2▲ 14×5 topics
- Trastuzumab2▲ 126×1 topic
- Cancer Treatment2▲ 24×2 topics
- Targeted Therapy2▲ 24×2 topics
- Radioimmunotherapy2▲ 182×1 topic
- Radiopharmaceuticals2▲ 182×1 topic
- Dendritic Cells2▲ 54×1 topic
- Epidemiology2▲ 1.20×15 topics
- Tumor Antigen2▲ 79×1 topic
- Tumor Microenvironment2▲ 9.7×3 topics
- Angiogenesis2▲ 13×5 topics
- Oxidative Stress1▲ 2.3×7 topics
- Biopharmaceuticals1▲ 64×2 topics
- Immune Checkpoint Blockade1▲ 28×1 topic
- Immunogenicity1▲ 76×2 topics
- PD-1 and PD-L11▲ 28×1 topic
- Cell Culture1▲ 26×2 topics
- Prevention1▲ 6.8×3 topics
- Public Health1▲ 1.98×3 topics
- Nanoparticles1▲ 2.2×4 topics
Which research topics does Cell Biologics (United States) publish most on?
By volume in 2022–2025: Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, HER2/EGFR in Cancer Research and Radiopharmaceutical Chemistry and Applications.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 3 works
- 2 CAR-T cell therapy research Oncology 3 works
- 3 HER2/EGFR in Cancer Research Oncology 2 works
- 4 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 2 works
- 5 Immunotherapy and Immune Responses Immunology 2 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 7 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 1 works
- 8 Protein purification and stability Molecular Biology 1 works
- 9 Liver physiology and pathology Hepatology 1 works
- 10 Cancer Cells and Metastasis Oncology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Cell Biologics (United States)'s research output changed?
Output in 2018–2022 was 32% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Chicago
- University of Chicago
- University of Illinois Chicago
- Loyola University Chicago
- Rush University Medical Center
- Illinois Institute of Technology
- DePaul University
- Experimental Station
- Boeing (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.